Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (MEPOCHUSS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00716651 |
Recruitment Status :
Completed
First Posted : July 16, 2008
Last Update Posted : June 15, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively in patients with asthma and which is characterized by prominent blood and tissue eosinophilia. The disease has a chronic smoldering course with a permanent need for medium to high corticosteroid doses. Available unselective immunosuppressive agents are often insufficient to reduce corticosteroid doses, to induce complete remission and to protect patients from disease flares which occur in more than 50 % of cases.
Interleukin-5 is the most potent cytokine regulating the production of eosinophil granulocytes which are the major effector cells in Churg-Strauss syndrome. Recently, an increased production of interleukin-5 was demonstrated in Churg-Strauss syndrome. Mepolizumab is a monoclonal IgG antibody targeting interleukin-5 and is effective in the treatment of the HES. The hypothesis of this study is, that mepolizumab will induce remission and allow for steroid reduction.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Churg Strauss Syndrome | Drug: mepolizumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | July 2010 |

- Drug: mepolizumab
750 mg mepolizumab iv q4wk until week 32
- Primary endpoint is the percentage of patients with Churg-Strauss Syndrome that attain remission [ Time Frame: 52 weeks ]
- Change in BVAS score [ Time Frame: 52 weeks ]
- Change in Disease Extent Index score [ Time Frame: 52 weeks ]
- Permanent End organ damage assessed by the Vasculitis Damage Index [ Time Frame: 52 weeks ]
- Time to remission [ Time Frame: 52 weeks ]
- Response, defined as a 50 % reduction of the BVAS score [ Time Frame: 52 weeks ]
- Time to response [ Time Frame: 52 weeks ]
- The frequency of relapses [ Time Frame: 52 weeks ]
- Blood eosinophil count [ Time Frame: 52 weeks ]
- Frequency of all AEs and SAEs [ Time Frame: 52 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- informed consent
- documented history of Churg Strauss Syndrome
- active disease
- subjects must complete screening and baseline assessment
- stable corticosteroid dose of > 12.5 mg prednisolone for at least one week
- treatment with cyclophosphamide (pulse or daily oral) or methotrexate or azathioprin or leflunomide in a stable dose for at least 4 weeks
- not pregnant or nursing
- negative pregnancy test and agree to practice birth control
Exclusion Criteria:
- life threatening disease or other critical illness deemed inappropriate for inclusion in the study by the principal investigator
- treatment with other immunosuppressive agents within 4 weeks prior to randomisation
- corticosteroid pulse of > 60 mg within the last three weeks prior to randomisation
- known secondary cause of eosinophilia
- no history or clinical features of vasculitis
- diagnosis of other primary systemic vasculitis
- currently active malignant disease
- abnormal laboratory values
- impaired cardiac function
- history of allergic reaction due to monoclonal antibodies
- prior treatment with anti-hIL-5 monoclonal antibody
- exposure to investigational drug within 30 days prior to randomisation
- positive pregnancy test

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716651
Germany | |
University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd | |
Bad Bramstedt, SH, Germany, 24576 |
Responsible Party: | Moosig, PD Dr. Frank Moosig, University Hospital Schleswig-Holstein |
ClinicalTrials.gov Identifier: | NCT00716651 |
Other Study ID Numbers: |
RBB1 EudraCT 2006-001791-20 |
First Posted: | July 16, 2008 Key Record Dates |
Last Update Posted: | June 15, 2012 |
Last Verified: | June 2012 |
Churg-Strauss Syndrome Syndrome Disease Pathologic Processes Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Systemic Vasculitis Vasculitis |
Vascular Diseases Cardiovascular Diseases Granuloma Lymphoproliferative Disorders Lymphatic Diseases Autoimmune Diseases Immune System Diseases |